Epigenetic silencing of TSHR gene in thyroid cancer patients in relation to their BRAF V600E mutation status

Endocrine

Volumn 47, Issue 2, 2014, Pages 449-455

  Khan, Mosin S ^a   Pandith, Arshad A ^a   Masoodi, Shariq R ^a,b   Wani, Khursheed A ^a   Ul Hussain, Mahboob ^c   Mudassar, Syed ^a  

^a SHER I KASHMIR INSTITUTE OF MEDICAL SCIENCES   (India)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF KASHMIR   (India)

Author keywords

Benign thyroid disease; Lymph node metastasis; Papillary thyroid cancer; Polymerase chain reaction; Thyroid stimulating hormone

Indexed keywords

B RAF KINASE; MITOGEN ACTIVATED PROTEIN KINASE; THYROTROPIN; THYROTROPIN RECEPTOR;

ADULT; ARTICLE; BRAF GENE; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA METHYLATION; DNA SEQUENCE; EPIGENETIC REPRESSION; EPIGENETICS; FEMALE; GENE EXPRESSION; GENE MUTATION; GENE SILENCING; HUMAN; HUMAN TISSUE; INDIA; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; PROMOTER REGION; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; THYROID CANCER; THYROTROPIN BLOOD LEVEL; TSHR GENE; ADENOCARCINOMA; AGED; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; MIDDLE AGED; MUTATION; PAPILLARY CARCINOMA; PATHOLOGY; THYROID TUMOR; VERY ELDERLY;

ADENOCARCINOMA, FOLLICULAR; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, PAPILLARY; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; MALE; MAP KINASE SIGNALING SYSTEM; MIDDLE AGED; MUTATION; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS B-RAF; RECEPTORS, THYROTROPIN; THYROID NEOPLASMS;

EID: 84911004617     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-014-0319-6     Document Type: Article

References (27)

1. M. Xing, Gene methylation in thyroid tumorigenesis. Endocrinology 148(3), 948–953 (2007)
2. H. Zuo et al., Downregulation of Rap1GAP through epigenetic silencing and loss of heterozygosity promotes invasion and progression of thyroid tumors. Cancer Res. 70(4), 1389–1397 (2010)
3. D. Russo, G. Damante, E. Puxeddu et al., Epigenetics of thyroid cancer and novel therapeutic targets. J. Mol. Endocrinol. 46(3), R73–R81 (2011)
4. F. Alvarez-Nuñez, E. Bussaglia et al., Thyroid Neoplasia Study Group PTEN promoter methylation in sporadic thyroid carcinomas. Thyroid 16(1), 17–23 (2006)
5. M. Xing, H. Usadel, Y. Cohen et al., Methylation of the thyroid-stimulating hormone receptor gene in epithelial thyroid tumors: a marker of malignancy and a cause of gene silencing. Cancer Res. 63(9), 2316–2321 (2003)
6. U. Schagdarsurengin, O. Gimm, H. Dralle, C. Hoang-Vu, R. Dammann, CpG island methylation of tumor-related promoters occurs preferentially in undifferentiated carcinoma. Thyroid 16(7), 633–642 (2006)
7. A.P. Bird, CpG rich islands and the function of DNA methylation. Nature (Lond) 321(6067), 209–213 (1986)
8. P.W. Ladenson, M.E. Ewertz, R.A. Dickey, Practical application of recombinant thyrotropin testing in clinical practice. Endocr. Pract. 7(3), 195–201 (2001)
9. J.A. Smith, C.Y. Fan, C. Zou, D. Bodenner et al., Methylation status of genes in papillary thyroid carcinoma. Arch. Otolaryngol. 133(10), 1006–1011 (2007)
10. M.O. Hoque, E. Rosenbaum, W.H. Westra et al., Quantitative assessment of promoter methylation profiles in thyroid neoplasms. J. Clin. Endocrinol. Metab. 90(7), 4011–4018 (2005)
11. J. Kim, A.E. Giuliano, R.R. Turner et al., Lymphatic mapping establishes the role of BRAF gene mutation in papillary thyroid carcinoma. Ann. Surg. 244(5), 799–810 (2006)
12. D.A. Kleiman, D. Buitrago, M.J. Crowley et al., Thyroid stimulating hormone increases iodine uptake by thyroid cancer cells during BRAF silencing. J. Surg. Res. 182(1), 85–93 (2013)
13. C. Durante, E. Puxeddu, E. Ferretti et al., BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. J. Clin. Endocrinol. Metab. 92(7), 2840–2847 (2007)
14. G.C. Maria, F. Nicoletta, B. Giuseppe, Epigenetic modifications and therapeutic prospects in human thyroid cancer. Front. Endocrinol. 3(40), 1–8 (2012)
15. W.A. Palmisano, K.K. Divine, G. Saccomanno et al., Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res. 60(21), 5954–5958 (2000)
16. E. Puxeddu, S. Filetti, BRAF mutation assessment in papillary thyroid cancer: are we ready to use it in clinical practice? Endocrine 45(1), 341–343 (2014)
17. H. Shao, X. Yu, C. Wang, Q. Wang, H. Guan, Midkine expression is associated with clinicopathological features and BRAF mutation in papillary thyroid cancer. Endocrine (2013). doi:10.1007/s12020-013-0068-y
18. L. Dingxie, H. Shuiying et al., Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant. Clin. Cancer Res. 13(4), 1341–1349 (2007)
19. G. Riesco-Eizaguirre, I. Rodriguez, A. DelaVieja et al., The BRAF V600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer. Cancer Res. 69(21), 8317–8324 (2009)
20. C. Romei, R. Ciampi, P. Faviana et al., BRAF V600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer. Endocr. Relat. Cancer 15(1), 511–523 (2008)
21. N. Mitsutake, J.A. Knauf, S. Mitsutake et al., Conditional BRAF V600E expression induces DNA synthesis, apoptosis, dedifferentiation, and chromosomal instability in thyroid PCCL3 cells. Cancer Res. 65(6), 2465–2473 (2005)
22. M. Xing, W.H. Westra et al., BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J. Clin. Endocrinol. Metab. 90(12), 6373–6379 (2005)
23. D. Chakravarty, E. Santos, M. Ryder et al., Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation. J. Clin. Investig. 121(12), 4700–4712 (2011)
24. C. Nucera, M.A. Nehs, S.S. Nagarkatti et al., Targeting BRAF V600E with PLX4720 displays potent anti-migratory and anti-invasive activity in preclinical models of human thyroid cancer. Oncologist 16(3), 296–305 (2011)
25. A.K. David, B. Daniel et al., Thyroid stimulating hormone increases iodine uptake by thyroid cancer cells during BRAF silencing. J. Surg. Res. 111(1), E1–E9 (2012)
26. M. Nilsson, Iodide handling by the thyroid epithelial cell. Exp. Clin. Endocrinol. Diabetes 109(5), 13–17 (2001)
27. L.S. Scheinbart, M.A. Johnson, L.A. Gross et al., Procainamide inhibits DNA methyltransferase in a human T cell line. J. Rheumatol. 18(4), 530–534 (1991)